{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:36:17Z","timestamp":1790793377908,"version":"4.1.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current nosological concept of \u03b1-synucleinopathies characterized by the presence of Lewy bodies (LBs) includes Parkinson\u2019s disease (PD), Parkinson\u2019s disease dementia (PDD), and dementia with Lewy bodies (DLB), for which the term \u201cLewy body disease\u201d (LBD) has recently been proposed due to their considerable clinical and pathological overlap. However, even this term does not seem to describe the true nature of this group of diseases. The subsequent discoveries of \u03b1-synuclein (\u03b1Syn), <jats:italic>SNCA<\/jats:italic> gene, and the introduction of new immunohistochemical methods have started intensive research into the molecular-biological aspects of these diseases. In light of today\u2019s knowledge, the role of LBs in the pathogenesis and classification of these nosological entities remains somewhat uncertain. An increasingly more important role is attributed to other factors as the presence of various LBs precursors, post-translational \u03b1Syn modifications, various \u03b1Syn strains, the deposition of other pathological proteins (particularly \u03b2-amyloid), and the discovery of selective vulnerability of specific cells due to anatomical configuration or synaptic dysfunction. Resulting genetic inputs can undoubtedly be considered as the main essence of these factors. Molecular\u2013genetic data indicate that not only in PD but also in DLB, a unique genetic architecture can be ascertained, predisposing to the development of specific disease phenotypes. The presence of LBs thus remains only a kind of link between these disorders, and the term \u201cdiseases with Lewy bodies\u201d therefore results somewhat more accurate.<\/jats:p>","DOI":"10.1038\/s41531-021-00273-9","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T11:02:59Z","timestamp":1641812579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Lewy body disease or diseases with Lewy bodies?"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-3160","authenticated-orcid":false,"given":"Kate\u0159ina","family":"Men\u0161\u00edkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslav","family":"Mat\u011bj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Colosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Tu\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Ehrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Hrabo\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00fdna","family":"Kola\u0159\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Vodi\u010dka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Vrt\u011bl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Proch\u00e1zka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7160-5283","authenticated-orcid":false,"given":"Martin","family":"Nevrl\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kaiserov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Kur\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Otruba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-3241","authenticated-orcid":false,"given":"Petr","family":"Ka\u0148ovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"273_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","volume":"126","author":"T Arendt","year":"2016","unstructured":"Arendt, T., Stieler, J. T. & Holzer, M. Tau and tauopathies. Brain Res. Bull. 126, 238\u2013292 (2016).","journal-title":"Brain Res. Bull."},{"key":"273_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/jclinpath-2019-205952","volume":"72","author":"GG Kovacs","year":"2019","unstructured":"Kovacs, G. G. Molecular pathology of neurodegenerative diseases: principles and practice. J. Clin. Pathol. 72, 725\u2013735 (2019).","journal-title":"J. Clin. Pathol."},{"key":"273_CR3","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","volume":"134","author":"Y Compta","year":"2011","unstructured":"Compta, Y. et al. Lewy \u2013 and Alzheimer-type pathologies in Parkinson\u2019s disease dementia: which is more important? Brain 134, 1493\u20131505 (2011).","journal-title":"Brain"},{"key":"273_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00401-013-1157-y","volume":"126","author":"GG Kovacs","year":"2013","unstructured":"Kovacs, G. G. et al. Non-alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 126, 365\u2013384 (2013).","journal-title":"Acta Neuropathol."},{"key":"273_CR5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00702-017-1821-9","volume":"125","author":"KA Jellinger","year":"2018","unstructured":"Jellinger, K. A. Dementia with Lewy bodies and Parkinson\u2019s disease dementia: current concepts and controversies. J. Neural Transm. 125, 615\u2013650 (2018).","journal-title":"J. Neural Transm."},{"key":"273_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/WCO.0000000000000664","volume":"32","author":"GG Kovacs","year":"2019","unstructured":"Kovacs, G. G. Are comorbidities compatible with a molecular pathological classification of neurodegenerative diseases? Curr. Opin. Neurol. 32, 279\u2013291 (2019).","journal-title":"Curr. Opin. Neurol."},{"key":"273_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jocn.2020.04.088","volume":"78","author":"S Das","year":"2020","unstructured":"Das, S., Zhang, Z. & Ang, L. C. Clinicopathological overlap of neurodegenerative diseases: a comprehensive review. J. Clin. Neurosci. 78, 30\u201333 (2020).","journal-title":"J. Clin. Neurosci."},{"key":"273_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40478-020-00914-9","volume":"8","author":"H Geut","year":"2020","unstructured":"Geut, H. et al. Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series. Acta Neuropathol. Commun. 8, 39 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"273_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ana.20819","volume":"59","author":"WR Galpern","year":"2006","unstructured":"Galpern, W. R. & Lang, A. E. Interface between tauopathies and synucleinopathies: a tale fo two proteins. Ann. Neurol. 59, 449\u2013458 (2006).","journal-title":"Ann. Neurol."},{"key":"273_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11910-018-0835-5","volume":"18","author":"C Foguem","year":"2018","unstructured":"Foguem, C. & Manckoundia, P. Lewy body disease: clinical and pathological \u201coverlap syndrome\u201c between synducleinopathies (Parkinson disease) and tauopathies (Alzheimer disease). Curr. Neurol. Nerosci. Rep. 18, 24 (2018).","journal-title":"Curr. Neurol. Nerosci. Rep."},{"key":"273_CR11","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1212\/WNL.57.8.1497","volume":"57","author":"AJ Hughes","year":"2001","unstructured":"Hughes, A. J., Daniel, S. E. & Lees, A. J. Improved accuracy of clinical diagnosis of Lewy body Parkinson\u2019s disease. Neurology 57, 1497\u20131499 (2001).","journal-title":"Neurology"},{"key":"273_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/jnnp.73.5.529","volume":"73","author":"A Schrag","year":"2002","unstructured":"Schrag, A., Ben-Shlomo, Y. & Quinn, N. How valid is the clinical diagnosis of Parkinson\u2019s disease in the community? J. Neurol. Neurosurg. Psychiatry 73, 529\u2013534 (2002).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"273_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mds.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan, I. et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18, 467\u2013486 (2003).","journal-title":"Mov. Disord."},{"key":"273_CR14","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic crietria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"273_CR15","doi-asserted-by":"publisher","first-page":"e5237","DOI":"10.1097\/MD.0000000000005237","volume":"95","author":"K Mensikova","year":"2016","unstructured":"Mensikova, K., Tuckova, L., Ehrmann, J. & Kanovsky, P. Unusual phenotype of pathologically confirmed progressive supranuclear palsy with autonomic dysfunction and cerebellar ataxia. Medicine 95, e5237 (2016).","journal-title":"Medicine"},{"key":"273_CR16","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"G H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger, G. et al. Clinical diagnosis of progresive supranuclear palsy: The Movement Disorders Society Criteria. Mov. Disord. 32, 853\u2013864 (2017).","journal-title":"Mov. Disord."},{"key":"273_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fneur.2018.00156","volume":"23","author":"L Marsili","year":"2018","unstructured":"Marsili, L., Rizzo, G. & Colosimo, C. Diagnostic criteria for Parkinson\u2019s disease: from James Parkinson to the concept of prodromal disease. Front. Neurol. 23, 156 (2018).","journal-title":"Front. Neurol."},{"key":"273_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/jnnp-2017-316844","volume":"89","author":"G Rizzo","year":"2018","unstructured":"Rizzo, G. et al. Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 89, 358\u2013366 (2018).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"273_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG Mc Keith","year":"2020","unstructured":"Mc Keith, I. G. et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 94, 743\u2013755 (2020).","journal-title":"Neurology"},{"key":"273_CR20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496\u2013503 (2013).","journal-title":"Neurology"},{"key":"273_CR21","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1136\/jnnp-2013-306948","volume":"85","author":"L Chare","year":"2014","unstructured":"Chare, L. et al. New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. J. Neurol. Neurosurg. Psychiatry 85, 866\u2013871 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"273_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.neurol.2018.07.001","volume":"174","author":"GU H\u00f6glinger","year":"2018","unstructured":"H\u00f6glinger, G. U., Respondek, G. & Kovacs, G. G. New classification of tauopathies. Rev. Neurol. 174, 664\u2013668 (2018).","journal-title":"Rev. Neurol."},{"key":"273_CR23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/WCO.0000000000000581","volume":"31","author":"G Respondek","year":"2018","unstructured":"Respondek, G., Levin, J. & H\u00f6glinger, G. U. Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. Curr. Opin. Neurol. 31, 448\u2013454 (2018).","journal-title":"Curr. Opin. Neurol."},{"key":"273_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jamaneurol.2019.4347","volume":"77","author":"E Jabbari","year":"2020","unstructured":"Jabbari, E. et al. Diagnosis accross the spectrum of progressive supranuclear palsy and corticobasal syndrome. JAMA Neurol. 77, 377\u2013378 (2020).","journal-title":"JAMA Neurol."},{"key":"273_CR25","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/S1353-8020(13)70017-8","volume":"20S1","author":"H McCann","year":"2014","unstructured":"McCann, H., Stevens, C. H., Cartwright, H. & Halliday, G. M. \u03b1-synucleinopathy phenotypes. Park. Relat. Disord. 20S1, S62\u2013S67 (2014).","journal-title":"Park. Relat. Disord."},{"key":"273_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cger.2019.09.014","volume":"36","author":"S Caproni","year":"2020","unstructured":"Caproni, S. & Colosimo, C. Diagnosis and differential diagnosis of Parkinson disease. Clin. Geriatr. Med. 36, 13\u201324 (2020).","journal-title":"Clin. Geriatr. Med."},{"key":"273_CR27","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"273_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00441-017-2706-9","volume":"373","author":"MG Spillantini","year":"2018","unstructured":"Spillantini, M. G. & Goedert, M. Neurodegeneration and the ordered assembly of \u03b1-synuclein. Cell Tissue Res. 373, 137\u2013148 (2018).","journal-title":"Cell Tissue Res."},{"key":"273_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00702-019-02025-9","volume":"126","author":"P Riederer","year":"2019","unstructured":"Riederer, P. et al. \u03b1-synuclein in Parkinson\u2019s disease: causal or bystander? J. Neural Transm. 126, 815\u2013840 (2019).","journal-title":"J. Neural Transm."},{"key":"273_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/jnc.13593","volume":"139","author":"DG Hernandez","year":"2016","unstructured":"Hernandez, D. G., Reed, X. & Singleton, A. B. Genetics in Parkinson disease: Mendelian versusu non-Mendelian inheritance. J. Neurochem. 139, 56\u201374 (2016).","journal-title":"J. Neurochem."},{"key":"273_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0780-8","volume":"17","author":"A Puschmann","year":"2017","unstructured":"Puschmann, A. New genes causing hereditary Parkinson\u2019s disease or parkinsonism. Curr. Neurol. Neurosci. Rep. 17, 66 (2017).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"273_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/hmg\/ddz183","volume":"28","author":"AB Singleton","year":"2019","unstructured":"Singleton, A. B. & Hardy, J. Progress in the genetic analysis of Parkinson\u2019s disease. Hum. Mol. Gen. 28, 215\u2013218 (2019).","journal-title":"Hum. Mol. Gen."},{"key":"273_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/bs.irn.2019.10.011","volume":"149","author":"A Weissbach","year":"2019","unstructured":"Weissbach, A., Wittke, C., Kasten, M. & Klein, C. \u201cAtypical\u201c Parkinson\u2019s disease \u2013 genetic. Int. Rev. Neurobiol. 149, 207\u2013237 (2019).","journal-title":"Int. Rev. Neurobiol."},{"key":"273_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","volume":"16","author":"E Tolosa","year":"2020","unstructured":"Tolosa, E., Vila, M., Klein, C. & Rascol, O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat. Rev. Neurol. 16, 97\u2013107 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"273_CR35","first-page":"729","volume":"95","author":"GR Wilson","year":"2014","unstructured":"Wilson, G. R. et al. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with alpha-synuclein pathology. Am. J. Med. Genet. 95, 729\u2013735 (2014).","journal-title":"Am. J. Med. Genet."},{"key":"273_CR36","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jamaneurol.2013.3646","volume":"70","author":"NJ Butcher","year":"2013","unstructured":"Butcher, N. J. et al. Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol. 70, 1359\u20131366 (2013).","journal-title":"JAMA Neurol."},{"key":"273_CR37","first-page":"pii: bcr0120113","volume":"2011","author":"M Takao","year":"2011","unstructured":"Takao, M. et al. Spinocerebellar ataxia type 2 is associated with Parkinsonism and Lewy body pathology. BMJ Case Rep. 2011, pii: bcr0120113685 (2011).","journal-title":"BMJ Case Rep."},{"key":"273_CR38","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre, M. et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov. Disord. 22, 1689\u20131707 (2007).","journal-title":"Mov. Disord."},{"key":"273_CR39","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.parkreldis.2005.02.012","volume":"11","author":"H Mori","year":"2005","unstructured":"Mori, H. Pathological substrate of dementia in Parkinson\u2019s disease-its relation to DLB and DBLD. Parkinsonism Relat. Disord. 11, S41\u2013S45 (2005).","journal-title":"Parkinsonism Relat. Disord."},{"key":"273_CR40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.bbadis.2008.07.006","volume":"1792","author":"KA Jellinger","year":"2009","unstructured":"Jellinger, K. A. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim. Biophys. Acta 1792, 730\u2013740 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"273_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nan.12648","volume":"47","author":"DS Hansen","year":"2021","unstructured":"Hansen, D. S. et al. Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson\u2019s disease dementia. Neuropathol. Appl. Neurobiol. 47, 143\u2013156 (2021).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"273_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"273_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/neup.12691","volume":"40","author":"K Wakabayashi","year":"2020","unstructured":"Wakabayashi, K. Where and how alpha-synuclein pathology spreads in Parkinson\u2019s disease. Neuropathology 40, 415\u2013425 (2020).","journal-title":"Neuropathology"},{"key":"273_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-020-02255-2","volume":"141","author":"J Attems","year":"2021","unstructured":"Attems, J. et al. Neuropathological consensus criteria for the evaluation of Lewy body pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 141, 159\u2013172 (2021).","journal-title":"Acta Neuropathol."},{"key":"273_CR45","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1152\/jn.00056.2019","volume":"121","author":"C Bove","year":"2019","unstructured":"Bove, C. & Travagli, R. A. Neurophysiology of the brainstem in Parkinson\u2019s disease. J. Neurophysiol. 121, 1856\u20131864 (2019).","journal-title":"J. Neurophysiol."},{"key":"273_CR46","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00415-019-09651-z","volume":"267","author":"LHM Keir","year":"2020","unstructured":"Keir, L. H. M. & Breen, D. P. New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson\u2019s disease. J. Neurol. 267, 288\u2013294 (2020).","journal-title":"J. Neurol."},{"key":"273_CR47","doi-asserted-by":"publisher","first-page":"102457","DOI":"10.1016\/j.nicl.2020.102457","volume":"28","author":"C Tremblay","year":"2020","unstructured":"Tremblay, C., Mei, J. & Frasnelli, J. Olfactory bulb surroundings can help to distinguish Parkinson\u2019s disease from non-parkinsonian olfactory dysfunction. Neuroimage Clin. 28, 102457 (2020).","journal-title":"Neuroimage Clin."},{"key":"273_CR48","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jnen\/nlz080","volume":"78","author":"CHH Adler","year":"2019","unstructured":"Adler, C. H. H. et al. Unified staging system for Lewy body disorders: clinicopathologic correlations ond comparison to Braak staging. J. Neuropathol. Exp. Neurol. 78, 891\u2013899 (2019).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"273_CR49","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s004019900168","volume":"100","author":"PM Mattila","year":"2000","unstructured":"Mattila, P. M., Rinne, J. O., Helenius, H., Dickson, D. W. & R\u00f6ytt\u00e4, S. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson\u2019s disease. Acta Neuropathol. 100, 285\u2013290 (2000).","journal-title":"Acta Neuropathol."},{"key":"273_CR50","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1007\/s00415-009-5243-y","volume":"256","author":"KA Jellinger","year":"2009","unstructured":"Jellinger, K. A. Formation and development of Lewy pathology: a critical update. J. Neurol. 256, S270\u2013S279 (2009).","journal-title":"J. Neurol."},{"key":"273_CR51","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WRG Gibb","year":"1988","unstructured":"Gibb, W. R. G. & Lees, A. J. The relevance of Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 51, 745\u2013752 (1988).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"273_CR52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181\u2013184 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"273_CR53","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/brain\/awf080","volume":"125","author":"AJ Hughes","year":"2002","unstructured":"Hughes, A. J., Daniel, S. E., Ben-Shlomo, Y. & Lees, A. J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125, 861\u2013870 (2002).","journal-title":"Brain"},{"key":"273_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak, H., Ghebremedhin, E., R\u00fcb, U., Bratzke, H. & Del Tredici, K. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res. 318, 121\u2013134 (2004).","journal-title":"Cell Tissue Res."},{"key":"273_CR55","first-page":"89","volume":"70","author":"H Braak","year":"2006","unstructured":"Braak, H. et al. Pathology associated with sporadic Parkinson\u2019s disease-where does it end? J. Neural Transm. 70, 89\u201397 (2006).","journal-title":"J. Neural Transm."},{"key":"273_CR56","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.parkreldis.2013.05.004","volume":"19","author":"A Batla","year":"2013","unstructured":"Batla, A. et al. Markedly asymmetric presentation in multiple system atrophy. Parkinsonism Relat. Disord. 19, 901\u2013905 (2013).","journal-title":"Parkinsonism Relat. Disord."},{"key":"273_CR57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jns.2013.03.008","volume":"329","author":"K Mensikova","year":"2013","unstructured":"Mensikova, K. et al. Progressive supranuclear palsy phenotype mimicking synucleinopathies. J. Neurol. Sci. 329, 34\u201337 (2013).","journal-title":"J. Neurol. Sci."},{"key":"273_CR58","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00401-018-1923-y","volume":"137","author":"K Mensikova","year":"2019","unstructured":"Mensikova, K. et al. Atypical parkinsonism of progressive supranuclear palsy-parkinsonism (PSP-P) phenotype with rare variants in FBXO7 and VPS35 genes associated with Lewy body pathology. Acta Neuropathol. 137, 171\u2013173 (2019).","journal-title":"Acta Neuropathol."},{"key":"273_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.irn.2019.10.003","volume":"149","author":"G Respondek","year":"2019","unstructured":"Respondek, G., Stamelou, M. & H\u00f6glinger, G. U. Classification of atypical parkinsonism per pathology versus phenotype. Int. Rev. Neurobiol. 149, 37\u201347 (2019).","journal-title":"Int. Rev. Neurobiol."},{"key":"273_CR60","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archneur.56.1.33","volume":"56","author":"DJ Gelb","year":"1999","unstructured":"Gelb, D. J., Oliver, E. & Gilman, S. Diagnostic criteria for Parkinson\u2019s disease. Arch. Neurol. 56, 33\u201339 (1999).","journal-title":"Arch. Neurol."},{"key":"273_CR61","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1007\/s00415-020-09985-z","volume":"267","author":"G Palermo","year":"2020","unstructured":"Palermo, G., Del Prete, E., Bonuccelli, U. & Ceravolo, R. Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between \u03b1-synucleinopathies. J. Neurol. 267, 3444\u20133456 (2020).","journal-title":"J. Neurol."},{"key":"273_CR62","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1474-4422(03)00351-X","volume":"2","author":"M Emre","year":"2003","unstructured":"Emre, M. Dementia associated with Parkinson\u2019s disease. Lancet Neurol. 2, 229\u2013237 (2003).","journal-title":"Lancet Neurol."},{"key":"273_CR63","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.parkreldis.2005.02.005","volume":"11","author":"L Guo","year":"2005","unstructured":"Guo, L., Itaya, M., Takanashi, M., Mizuno, Y. & Mori, H. Relationship between Parkinson disease with dementia and dementia with Lewy bodies. Park. Relat. Disord. 11, 305\u2013309 (2005).","journal-title":"Park. Relat. Disord."},{"key":"273_CR64","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fneur.2018.00123","volume":"9","author":"G Aldridge","year":"2018","unstructured":"Aldridge, G., Birnschein, A., Denburg, N. L. & Narayanan, N. S. Parkinson\u2019s disease dementia and dementia with Lewy bodies have similar neuropsychological profiles. Front. Neurol. 9, 123 (2018).","journal-title":"Front. Neurol."},{"key":"273_CR65","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","volume":"47","author":"IG McKeith","year":"1996","unstructured":"McKeith, I. G. et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 47, 1113\u20131124 (1996).","journal-title":"Neurology"},{"key":"273_CR66","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: Third Report of the DLB Consortium. Neurology 65, 1863\u20131872 (2005).","journal-title":"Neurology"},{"key":"273_CR67","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies. Fourth Consensus Report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"273_CR68","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/WAD.0b013e31826f040d","volume":"27","author":"B Kaur","year":"2013","unstructured":"Kaur, B. et al. Extrapyramidal signs by dementia severity in Alzheimer disease and dementia with Lewy bodies. Alzheimer Dis. Assoc. Disord. 27, 226\u2013232 (2013).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"273_CR69","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","volume":"386","author":"Z Walker","year":"2015","unstructured":"Walker, Z., Possin, K. L., Boeve, B. F. & Aarsland, D. Lewy bodies dementias. Lancet 386, 1683\u20131697 (2015).","journal-title":"Lancet"},{"key":"273_CR70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"TF Outeiro","year":"2019","unstructured":"Outeiro, T. F. et al. Dementia with Lewy bodies: an update and outlook. Mol. Neurodegener. 14, 5 (2019).","journal-title":"Mol. Neurodegener."},{"key":"273_CR71","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/alzrt274","volume":"6","author":"PC Donaghy","year":"2014","unstructured":"Donaghy, P. C. & McKeith, I. G. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res. Ther. 6, 46 (2014).","journal-title":"Alzheimers Res. Ther."},{"key":"273_CR72","first-page":"435","volume":"22","author":"SN Gomperts","year":"2016","unstructured":"Gomperts, S. N. Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Continuum 22, 435\u2013463 (2016).","journal-title":"Continuum"},{"key":"273_CR73","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.12688\/f1000research.11725.1","volume":"6","author":"RS Weil","year":"2017","unstructured":"Weil, R. S., Lashley, T. L., Bras, J., Schrag, A. E. & Schott, J. M. Current concepts and controversies in the pathogenesis of Parkinson\u2019s disease dementia and dementia with Lewy bodies. F1000Res 6, 1604 (2017).","journal-title":"F1000Res"},{"key":"273_CR74","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00401-010-0711-0","volume":"120","author":"WJ Schulz-Schaeffer","year":"2010","unstructured":"Schulz-Schaeffer, W. J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson\u2019s disease and Parkinson\u2019s disease dementia. Acta Neuropathol. 120, 131\u2013143 (2010).","journal-title":"Acta Neuropathol."},{"key":"273_CR75","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/jnen\/nlw087","volume":"75","author":"Z Rohan","year":"2016","unstructured":"Rohan, Z., Milenkovic, I., Lutz, M. I., Matej, R. & Kovacs, G. G. Shared and distinct patterns of oligodendroglial response in synucleinopathies and tauopathies. J. Neuropathol. Exp. Neurol. 75, 1100\u20131109 (2016).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"273_CR76","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1093\/brain\/awx275","volume":"140","author":"M Colom-Cadena","year":"2017","unstructured":"Colom-Cadena, M. et al. Synaptic phosphorylated alpha-synuclein in dementia with Lewy bodies. Brain 140, 3204\u20133214 (2017).","journal-title":"Brain"},{"key":"273_CR77","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/brain\/awv040","volume":"138","author":"RF Roberts","year":"2015","unstructured":"Roberts, R. F., Wade-Martins, R. & Alegre-Abarrategui, J. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson\u2019s disease brain. Brain 138, 1642\u20131657 (2015).","journal-title":"Brain"},{"key":"273_CR78","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/mds.26796","volume":"31","author":"RB Postuma","year":"2016","unstructured":"Postuma, R. B. et al. Abolishing the 1-year rule: how much evidence will be enough? Mov. Disord. 31, 1623\u20131627 (2016).","journal-title":"Mov. Disord."},{"key":"273_CR79","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/JAD-160322","volume":"54","author":"I van Steenoven","year":"2016","unstructured":"van Steenoven, I. et al. Cerebrospinal fluid Alzheimer\u2019s disease biomarkers across the spectrum of Lewy body diseases: results from a large multicenter cohort. J. Alzheimers Dis. 54, 287\u2013295 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"273_CR80","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/gps.2496","volume":"26","author":"M Andersson","year":"2011","unstructured":"Andersson, M., Zetterberg, H., Minthon, L., Blennow, K. & Londos, E. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson\u2019s disease dementia. Int. J. Geriatr. Psychiatry 26, 100\u2013105 (2011).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"273_CR81","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin, D. J. et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 16, 55\u201365 (2017).","journal-title":"Lancet Neurol."},{"key":"273_CR82","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/jnr.21352","volume":"85","author":"T Kurata","year":"2007","unstructured":"Kurata, T. et al. Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1. J. Neurosci. Res. 85, 2246\u20132252 (2007).","journal-title":"J. Neurosci. Res."},{"key":"273_CR83","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1096\/fj.08-120410","volume":"23","author":"T Duka","year":"2009","unstructured":"Duka, T., Duka, V., Joyce, J. N. & Sidhu, A. Alpha-Synuclein contributes to GSK-3betacatalyzed Tau phosphorylation in Parkinson\u2019s disease models. FASEB J. 23, 2820\u20132830 (2009).","journal-title":"FASEB J."},{"key":"273_CR84","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739\u201329752 (2006).","journal-title":"J. Biol. Chem."},{"key":"273_CR85","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13195-014-0077-y","volume":"6","author":"M Swirski","year":"2014","unstructured":"Swirski, M. et al. Evaluating the relationship between amyloid-beta and alpha-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson\u2019s disease. Alzheimers Res. Ther. 6, 77 (2014).","journal-title":"Alzheimers Res. Ther."},{"key":"273_CR86","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.expneurol.2007.11.019","volume":"210","author":"K Obi","year":"2008","unstructured":"Obi, K. et al. Relationship of phosphorylated alphasynuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp. Neurol. 210, 409\u2013420 (2008).","journal-title":"Exp. Neurol."},{"key":"273_CR87","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.expneurol.2012.11.020","volume":"240","author":"DG Walker","year":"2013","unstructured":"Walker, D. G. et al. Changes in properties of serine 129 phosphorylated \u03b1-synuclein with progression of Lewy-type histopathology in human brains. Exp. Neurol. 240, 190\u2013204 (2013).","journal-title":"Exp. Neurol."},{"key":"273_CR88","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1212\/01.wnl.0000242630.52203.8f","volume":"67","author":"JE Galvin","year":"2006","unstructured":"Galvin, J. E., Pollack, J. & Morris, J. C. Clinical phenotype of Parkinson disease dementia. Neurology 67, 1605\u20131611 (2006).","journal-title":"Neurology"},{"key":"273_CR89","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mds.23795","volume":"27","author":"KA Jellinger","year":"2012","unstructured":"Jellinger, K. A. Neuropathology of sporadic Parkinson\u2019s disease: evaluation and changes of concepts. Mov. Disord. 27, 8\u201330 (2012).","journal-title":"Mov. Disord."},{"key":"273_CR90","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1212\/WNL.0b013e318278fe32","volume":"79","author":"JM Milber","year":"2012","unstructured":"Milber, J. M. et al. Lewy pathology is not the first signof degeneration in vulnerable neurons in Parkinson disease. Neurology 79, 2307\u20132314 (2012).","journal-title":"Neurology"},{"key":"273_CR91","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1750-3639.2011.00509.x","volume":"22","author":"T Kanazawa","year":"2012","unstructured":"Kanazawa, T. et al. Pale neurites, premature \u03b1-synuclein aggregates with centripetal extension from axon collaterals. Brain Pathol. 22, 67\u201378 (2012).","journal-title":"Brain Pathol."},{"key":"273_CR92","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1212\/WNL.0b013e318278b6a7","volume":"79","author":"WJ Schulz-Schaeffer","year":"2012","unstructured":"Schulz-Schaeffer, W. J. Neurodegeneration in Parkinson disease: moving Lewy bodies out of focus. Neurology 79, 2298\u20132299 (2012).","journal-title":"Neurology"},{"key":"273_CR93","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3390\/biom5031467","volume":"5","author":"WJ Schulz-Schaeffer","year":"2015","unstructured":"Schulz-Schaeffer, W. J. Is cell death primary or secondary in the pathophysiology of idiopathic Parkinson\u2019s disease? Biomolecules 5, 1467\u20131479 (2015).","journal-title":"Biomolecules"},{"key":"273_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3575","volume":"4","author":"L Bousset","year":"2013","unstructured":"Bousset, L. et al. Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 4, 2575 (2013).","journal-title":"Nat. Commun."},{"key":"273_CR95","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cell.2013.05.057","volume":"154","author":"JL Guo","year":"2013","unstructured":"Guo, J. L. et al. Distinct \u03b1-synuclein strains differentially promote tau inclusions in neurons. Cell 154, 103\u2013117 (2013).","journal-title":"Cell"},{"key":"273_CR96","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1523\/JNEUROSCI.5427-08.2009","volume":"29","author":"CY Chung","year":"2009","unstructured":"Chung, C. Y., Koprich, J. B., Siddiqi, H. & Isacson, O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 29, 3365\u20133373 (2009).","journal-title":"J. Neurosci."},{"key":"273_CR97","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40478-017-0416-x","volume":"5","author":"CW Ip","year":"2017","unstructured":"Ip, C. W. et al. AAV1\/2 - induced overexpression of A53T-\u03b1-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson\u2019s disease. Acta Neuropathol. Commun. 5, 11 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"273_CR98","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1016\/j.neubiorev.2013.09.003","volume":"37","author":"J Gratwicke","year":"2013","unstructured":"Gratwicke, J. et al. The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia? Neurosci. Biobehav. Rev. 37, 2676\u20132688 (2013).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"273_CR99","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00213-010-2089-z","volume":"213","author":"MW Hale","year":"2013","unstructured":"Hale, M. W. & Lowry, C. A. Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits. Psychopharmacology 213, 243\u2013264 (2013).","journal-title":"Psychopharmacology"},{"key":"273_CR100","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1212\/01.WNL.0000150591.33787.A4","volume":"64","author":"S Zaja-Milatovic","year":"2005","unstructured":"Zaja-Milatovic, S. et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64, 545\u2013547 (2005).","journal-title":"Neurology"},{"key":"273_CR101","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.neuroscience.2005.01.007","volume":"132","author":"B Stephens","year":"2005","unstructured":"Stephens, B. et al. Evidence of a breakdown of corticostriatal connections in Parkinson\u2019s disease. Neuroscience 132, 741\u2013754 (2005).","journal-title":"Neuroscience"},{"key":"273_CR102","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1093\/brain\/aws174","volume":"135","author":"O Goker-Alpan","year":"2012","unstructured":"Goker-Alpan, O. et al. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain 135, 2440\u20132448 (2012).","journal-title":"Brain"},{"key":"273_CR103","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","volume":"70","author":"MA Nalls","year":"2013","unstructured":"Nalls, M. A. et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 70, 727\u2013735 (2013).","journal-title":"JAMA Neurol."},{"key":"273_CR104","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1093\/hmg\/ddu334","volume":"23","author":"J Bras","year":"2014","unstructured":"Bras, J. et al. Genetic analysis implicates APOE, SNCA and suggest lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum. Mol. Gen. 23, 6139\u20136146 (2014).","journal-title":"Hum. Mol. Gen."},{"key":"273_CR105","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","volume":"16","author":"A Schrag","year":"2017","unstructured":"Schrag, A., Siddiqui, U. F., Anastasiou, Z. & Weintraub Schott, J. M. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: a cohort study. Lancet Neurol. 16, 66\u201375 (2017).","journal-title":"Lancet Neurol."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00273-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00273-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00273-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:05:47Z","timestamp":1669298747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00273-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["273"],"URL":"https:\/\/doi.org\/10.1038\/s41531-021-00273-9","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"17 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C. reports personal fees from Ipsen, personal fees from BIAL, personal fees from Zambon, and personal fees from Abbvie, outside the submitted work. The other authors declare no financial or other conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}